All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 17, 2021
Home
» Pralsetinib shows promising activity in RET-mutant MTC in the phase I/II ARROW trial
Pralsetinib shows promising activity in RET-mutant MTC in the phase I/II ARROW trial
Oct. 6, 2020
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=174201
BioWorld Science
Related Articles
Bridge Biotherapeutics begins phase I/II trial of BBT-176 in EGFR-mutant NSCLC with C797S
